Mackenzie Financial Corp Sells 1,182 Shares of Catalent, Inc. (NYSE:CTLT)

Mackenzie Financial Corp lowered its stake in shares of Catalent, Inc. (NYSE:CTLT) by 17.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,421 shares of the company’s stock after selling 1,182 shares during the period. Mackenzie Financial Corp’s holdings in Catalent were worth $244,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the stock. Cadian Capital Management LP boosted its stake in Catalent by 91.0% during the third quarter. Cadian Capital Management LP now owns 5,304,784 shares of the company’s stock valued at $241,527,000 after buying an additional 2,526,750 shares during the last quarter. Barclays PLC boosted its position in shares of Catalent by 41.7% during the 3rd quarter. Barclays PLC now owns 4,797,718 shares of the company’s stock valued at $218,440,000 after acquiring an additional 1,412,058 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Catalent by 65.9% in the third quarter. Ameriprise Financial Inc. now owns 3,483,494 shares of the company’s stock valued at $158,601,000 after purchasing an additional 1,384,313 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Catalent by 50.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,536,313 shares of the company’s stock worth $69,948,000 after purchasing an additional 516,464 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in Catalent by 29.6% during the third quarter. Assenagon Asset Management S.A. now owns 1,875,829 shares of the company’s stock valued at $85,406,000 after purchasing an additional 428,260 shares in the last quarter.

Catalent Stock Performance

Shares of NYSE:CTLT opened at $55.92 on Monday. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48. The firm has a market cap of $10.12 billion, a PE ratio of -8.22, a price-to-earnings-growth ratio of 6.03 and a beta of 1.20. The firm’s 50 day simple moving average is $56.68 and its 200-day simple moving average is $48.71. Catalent, Inc. has a one year low of $31.45 and a one year high of $60.20.

Catalent (NYSE:CTLT) last issued its earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period last year, the firm earned $0.62 earnings per share. The company’s revenue for the quarter was down 10.2% on a year-over-year basis. As a group, equities analysts predict that Catalent, Inc. will post 0.28 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CTLT. UBS Group reaffirmed a “neutral” rating and issued a $63.50 price target (up previously from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Barclays lifted their target price on Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. Stephens restated an “equal weight” rating and set a $63.50 price target on shares of Catalent in a report on Thursday, April 4th. Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research report on Tuesday, February 20th. Finally, StockNews.com initiated coverage on shares of Catalent in a research note on Saturday. They issued a “sell” rating on the stock. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $52.46.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.